Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZN-d5 in Relapsed/Refractory AL Amyloidosis
NCT05199337Phase 2Completed
- Sponsor
- Zentalis Pharmaceuticals
- Start
- Nov 2021
- Primary completion
- Feb 2024
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of asaretoclax in amyloid light chain amyloidosis, sponsored by Zentalis Pharmaceuticals. Started Nov 2021; status: completed.
02
Drugs
asaretoclax
03
Conditions
amyloid light chain amyloidosis
Beyond the preview
Go deeper on NCT05199337.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05199337.